In addition, the results of one SR/MA [27] showed significant efficacy of XFZY in the treatment of AF (low-quality evidence), DAP (low-quality evidence), WBV (low-quality evidence), PV (extremely low-quality evidence), FB (extremely low-quality evidence), NO (low-quality evidence), and ET-1 (low-quality evidence). The gene discussed is EDN1; the disease is atrial fibrillation.